Invenomic Capital Management’s Juniper Networks JNPR Stock Holding History

Invenomic Capital Management’s Portfolio JNPR Stock Details JNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-8,767	Closed	-$168K	–	171
2020 Q1	$168K	Sell	8,767 -608	-6%	-$13.6K	0.14%	124
2019 Q4	$231K	Buy	+9,375	New	+$231K	0.09%	106

Other funds holding JNPR

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invenomic Capital Management's JNPR Position: Q2 2020 in Review

Invenomic Capital Management sold out of Juniper Networks (JNPR) in Q2 2020, closing a stake of 8,767 shares — an estimated $168K sold.

Invenomic Capital Management first reported a position in JNPR in Q4 2019 and held it in 2 quarters. The position peaked at $231K in Q4 2019. 430 funds tracked by Wall St. Rank hold JNPR as of Q2 2020.

Invenomic Capital Management reported no remaining Juniper Networks position as of Q2 2020 after selling out during the quarter.
Invenomic Capital Management sold 8,767 Juniper Networks shares in Q2 2020, an estimated $168K.
Invenomic Capital Management first reported a position in Juniper Networks in Q4 2019 and held it in 2 quarters.
Invenomic Capital Management's Juniper Networks position peaked at $231K in Q4 2019.
430 funds tracked by Wall St. Rank held Juniper Networks as of Q2 2020.

Based on Invenomic Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.